Linked Life Data

19269014

Source:http://linkedlifedata.com/resource/pubmed/id/19269014

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19269014rdf:typepubmed:Citationlld:pubmed
pubmed-article:19269014lifeskim:mentionsumls-concept:C0242957lld:lifeskim
pubmed-article:19269014lifeskim:mentionsumls-concept:C0024623lld:lifeskim
pubmed-article:19269014lifeskim:mentionsumls-concept:C1521871lld:lifeskim
pubmed-article:19269014lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:19269014pubmed:issue6lld:pubmed
pubmed-article:19269014pubmed:dateCreated2009-5-15lld:pubmed
pubmed-article:19269014pubmed:abstractTextHer-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab). The potential benefit of anti-Her-2 therapy is currently investigated in several other HER-2-amplified cancers including gastric cancer. Although HER-2 amplification occurs in more than 10% of gastric cancers, potential heterogeneity of HER-2 amplification and overexpression could represent a major drawback for anti-Her-2 therapy. To address the potential applicability of trastuzumab in gastric cancer, tissue microarray sections of 166 gastric adenocarcinomas and 69 lymph node metastases were analyzed for Her-2 overexpression and amplification using Food and Drug Administration-approved reagents for immunohistochemistry and fluorescence in situ hybridization. HER-2 amplification was seen in 27 (16%) of 166 gastric adenocarcinomas. Amplification was typically high level with more than 20 HER-2 copies per tumor cell and a HER-2/centromere 17 ratio >3. Amplification was associated with intestinal tumor phenotype but unrelated to survival, grading, pT, pN, or pM. Identical HER-2 status was found in primary tumor and their matched lymph node metastases. Moreover, HER-2 and Topoisomerase IIalpha coamplification analysis of 3 to 16 large sections from 8 Her-2-positive gastric cancers did not reveal any heterogeneity of the amplicon site. The high level of HER-2 amplification in combination with the homogeneity of its expression in primary and metastatic tumors argues for a possible therapeutic utility of trastuzumab in HER-2-amplified gastric adenocarcinomas.lld:pubmed
pubmed-article:19269014pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19269014pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19269014pubmed:languageenglld:pubmed
pubmed-article:19269014pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19269014pubmed:citationSubsetIMlld:pubmed
pubmed-article:19269014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19269014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19269014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19269014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19269014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19269014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19269014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19269014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19269014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19269014pubmed:statusMEDLINElld:pubmed
pubmed-article:19269014pubmed:monthJunlld:pubmed
pubmed-article:19269014pubmed:issn1532-8392lld:pubmed
pubmed-article:19269014pubmed:authorpubmed-author:SauterGuidoGlld:pubmed
pubmed-article:19269014pubmed:authorpubmed-author:IzbickiJakob...lld:pubmed
pubmed-article:19269014pubmed:authorpubmed-author:BokemeyerCars...lld:pubmed
pubmed-article:19269014pubmed:authorpubmed-author:SimonRonaldRlld:pubmed
pubmed-article:19269014pubmed:authorpubmed-author:YekebasEmreElld:pubmed
pubmed-article:19269014pubmed:authorpubmed-author:BrümmendorfTi...lld:pubmed
pubmed-article:19269014pubmed:authorpubmed-author:MirlacherMart...lld:pubmed
pubmed-article:19269014pubmed:authorpubmed-author:KaifiJussuf...lld:pubmed
pubmed-article:19269014pubmed:authorpubmed-author:MarxAndreas...lld:pubmed
pubmed-article:19269014pubmed:authorpubmed-author:TharunLarsLlld:pubmed
pubmed-article:19269014pubmed:authorpubmed-author:MuthJohannaJlld:pubmed
pubmed-article:19269014pubmed:authorpubmed-author:DancauAna-Mar...lld:pubmed
pubmed-article:19269014pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19269014pubmed:volume40lld:pubmed
pubmed-article:19269014pubmed:ownerNLMlld:pubmed
pubmed-article:19269014pubmed:authorsCompleteYlld:pubmed
pubmed-article:19269014pubmed:pagination769-77lld:pubmed
pubmed-article:19269014pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:meshHeadingpubmed-meshheading:19269014...lld:pubmed
pubmed-article:19269014pubmed:year2009lld:pubmed
pubmed-article:19269014pubmed:articleTitleHER-2 amplification is highly homogenous in gastric cancer.lld:pubmed
pubmed-article:19269014pubmed:affiliationInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany. a.marx@uke.delld:pubmed
pubmed-article:19269014pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:2064entrezgene:pubmedpubmed-article:19269014lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19269014lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19269014lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19269014lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19269014lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19269014lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19269014lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19269014lld:pubmed